GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, raised $15 million by offering 1.5 million shares at $10, below the expected $15 offer price. GlobeImmune plans to list on the NASDAQ under the symbol GBIM. Aegis Capital Corp. acted as lead manager on the deal.
